COOHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering The Cooper Cos., Inc. hold a median 12-month price target of $85 — +12.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 17 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores The Cooper Cos., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Momentum (38): The shares have been drifting down relative to others.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on COO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +12.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Citigroup | Maintains | Neutral | $76 → $80 |
| 28 July 2026 | UBS | Initiates | Neutral | $75 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $69 → $76 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 8 June 2026 | BNP Paribas | Maintains | Outperform | — |
| 5 June 2026 | Baird | Maintains | Outperform | — |
| 5 June 2026 | JP Morgan | Maintains | Neutral | — |
| 5 June 2026 | Needham | Maintains | Buy | — |
| 5 June 2026 | Stifel | Maintains | Buy | — |
| 5 June 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 June 2026 | Mizuho | Maintains | Outperform | — |
| 1 June 2026 | Piper Sandler | Reiterates | Overweight | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | Barclays | Maintains | Overweight | — |
| 6 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | Needham | Maintains | Buy | — |
| 3 Feb 2026 | Needham | Maintains | Buy | — |
| 26 Jan 2026 | Barclays | Maintains | Overweight | — |
| 8 Dec 2025 | Citigroup | Maintains | Neutral | — |
| 8 Dec 2025 | Goldman Sachs | Maintains | Sell | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 12% of US stocks
Cheaper than 36% of US stocks
Cheaper than 50% of US stocks
Cheaper than 17% of US stocks
Higher than 47% of US stocks
Higher than 45% of US stocks
Higher than 81% of US stocks
Higher than 29% of US stocks
Higher than 61% of US stocks
Higher than 49% of US stocks
Higher than 62% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own The Cooper Cos., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights The Cooper Companies (COO) as a strong growth stock, using its Zacks Style Scores feature to identify the company among top growth opportunities for investors.
Why it matters — COO watchers would care because the piece positions the company favorably within Zacks' growth-stock framework, reinforcing its standing among strong investment candidates.
Zacks published an article highlighting Cooper Companies' premium lens migration, MiSight growth, and fertility recovery as sources of long-term upside. It also notes that Asia-Pacific, tariff, and foreign-exchange pressures present headwinds for the company.
Why it matters — A COO watcher would care because the piece points to specific growth drivers in its contact lens and fertility segments while flagging the key risks that could affect its outlook.
The Cooper Companies was upgraded to a Zacks Rank #2 (Buy) by Zacks Investment Research, reflecting growing optimism about the company's earnings prospects.
Why it matters — A COO watcher would care because the upgrade signals increased analyst confidence in the company's near-term earnings outlook.
CooperCompanies announced it will report its third quarter 2026 financial results on Wednesday, September 9, 2026, at 4:15 PM ET, and will host a conference call at 5:00 PM ET to discuss the results and corporate developments.
Why it matters — COO watchers need to know the scheduled date for the quarterly earnings release and conference call to plan ahead for the financial update.
Oakmark Global Fund reported that it initiated a position in Cooper Companies (The Cooper Cos.) during the second quarter of 2026, citing what it views as an attractive entry point relative to its estimate of intrinsic value.
Why it matters — A major fund's decision to initiate a position in COO signals institutional confidence in the company's valuation and prospects.
The 16 Wall Street analysts covering The Cooper Cos., Inc. have a median 12-month price target of $85, with estimates ranging from $66 to $92. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering The Cooper Cos., Inc., 10 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Cooper Cos., Inc. 77 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, The Cooper Cos., Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +12.2% from the last close, and Ticker Nerd's factor model ranks The Cooper Cos., Inc. 77 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Cooper Cos., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $66 to $92 over the next 12 months.
The Cooper Cos., Inc. returned +3.0% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
The Cooper Companies, Inc. is a global medical device company focused on eyecare and women’s health, headquartered in San Ramon, California.
The most recent item we track (Zacks Investment Research, 18 Aug 2026): "Here's Why The Cooper Companies (COO) is a Strong Growth Stock". Zacks Investment Research highlights The Cooper Companies (COO) as a strong growth stock, using its Zacks Style Scores feature to identify the company among top growth opportunities for investors.
The Cooper Companies, Inc. is a global medical device company focused on eyecare and women’s health, headquartered in San Ramon, California. The business operates through two main segments: CooperVision and CooperSurgical. CooperVision develops, manufactures, and markets a broad portfolio of contact lenses, including spherical, toric, and multifocal designs that address conditions such as myopia, hyperopia, astigmatism, and presbyopia, as well as products aimed at managing ocular dryness and eye fatigue. Its branded lens families, such as Proclear, Biofinity, MyDay, and Clariti, serve eye-care professionals and contact lens wearers worldwide and position the company as a major participant in the soft contact lens market. CooperSurgical provides medical devices, equipment, and consumables for fertility, in vitro fertilization (IVF), and women’s health, supporting clinical workflows across the reproductive care continuum. Within this segment, the company offers products used in assisted reproductive technology, obstetrics, gynecology, and long-acting reversible contraception, making it a notable supplier to hospitals, clinics, and specialty practices focused on women, babies, and family health.
CEO Mr. Albert G. White III · 15,000 employees · United States · https://www.coopercos.com